| Protocol 133: Phase I-II Study of HER2 Vaccination with poly(I) • poly(C-12-U)(Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients Scientific DescriptionClinical Description |
| Protocol 135: Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently with a HER2 ICD Peptide-Based Vaccine and Trastuzumab in Patients with Stage IV Breast Cancer |